30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium 2018
Meet with Q2 Solutions at the 30th Molecular Targets and Cancer Therapeutics Symposium 2018 and learn how we can partner with you into leveraging latest innovations in cancer research and drug development
About This EventQ2 Solutions’ has integrated industry leading central lab and precision medicine capabilities, dedicated to enhancing and accelerating your cancer research and drug development. From biomarkers, companion diagnostics, esoteric testing, high quality data, bioinformatics and analytics, to robust logistics and sample management our dedicated project managers strive to power your oncology study every step of the way.
We leverage and support breakthrough cancer research and insights through our genomics unit – we can help you uncover invaluable insights from your clinical trial data and design smarter studies, employing latest precision medicine findings. When it comes to precious samples, partner with us for the genomic information you need to succeed. We can begin with biomarker identification programs in early development and then progressively develop candidate biomarkers into research-appropriate tests and market-ready companion diagnostics.
Q2 Solutions operates a global footprint and quality systems to ensure assay development and validation across a wide spectrum of patient populations for your targeted therapeutic and companion diagnostic. Our experts in biomarker discovery are providing a better understanding of therapeutic targets, molecular signaling, drug biology and patient response to support your cancer research and clinical outcomes.
- Please plan attend our poster presentation on November 16th, titled "RNA sequencing identifies differences in immune profiles of tumors from pediatric neuroblastoma patients with Opsoclonus myoclonus syndrome.”
- Authors: Victor Weigman, Director, Translational Genomics and Martin Buchkovich, Sr. Bioinformaticist
We look forward to meeting you in Dublin.
Director, Translational Genomics
Dr. Victor Weigman, Ph.D. is Director, Translational Genomics at Q2 Solutions, a Quintiles Quest Joint Venture, leading the group with a goal of continued facilitation of pre-clinical drug development through biomarker identification. Ongoing research revolves around the genomic profiling of solid tumors from both DNA and RNA approaches including the development of robust assays that can be leveraged as laboratory developed tests.
Dr. Weigman brings more than 10 years of biomarker discovery research with genomics, with a majority of them dedicated to Expression Analysis (EA), a Q2 Solutions Company. He has published 14 papers on biomarker identification and assay development and has contributed to the development and launch of several genomic CLIA Assays. Additionally, Dr. Weigman is involved in pharma partnerships for clinical trial development using genomic profiling technologies.
Dr. Weigman obtained his Ph.D. at the University of North Carolina in Biology and Bioinformatics within the Lineberger Comprehensive Cancer Center.
Updated as of September 2018.
Senior Bioinformaticist, Translational Genomics
Martin Buchkovich, Ph.D is a senior bioinformaticist in Translational Genomics at Q2 Solutions | EA Genomics. In his current role, he is responsible for implementing strategies that improve the quality of and increase the utility of genomics data, such as data used in profiling solid tumors and biomarker development. These activities include implementing new and improving current analysis pipelines, developing new algorithms, and working with clients to create custom solutions that meet their analysis needs.
Dr. Buchkovich has more than 9 years of experience analyzing next generation sequencing data and the genomics underlying human health and disease, and has authored 12 peer-reviewed papers. He earned a Bachelor’s degree in Bioinformatics from Brigham Young University, followed by a Ph.D. in Computational Biology and Bioinformatics at the University of North Carolina at Chapel Hill.
Updated as of September 2018.